S-Alpha Therapeutics, Inc.
8
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia
Role: lead
Pivotal Trial of SAT-014 for Trauma and Stressor-Related Disorder Symptoms
Role: lead
Exploratory Trial of SAT-003 in Cancer Cachexia Patients With Discontinued Chemotherapy
Role: lead
Exploratory Study on the Effect of SAT-001 on Choroidal Thickness in Pediatric Myopia Patients
Role: lead
Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children
Role: lead
Clinical Trial to Preliminarily Assess the Safety and Feasibility of SAT-014, a Software for Alleviating Symptoms of Trauma and Stress-related Disorders
Role: lead
Exploratory Study of SAT-001 in Treatment of Pediatric Patient With Myopia
Role: lead
An Investigator-initiated, Explorative Trial Evaluating the Effect of SAT-008 in Healthy Adults
Role: collaborator
All 8 trials loaded